Episode summary: The conversation explores the complexity of acquired resistance in cancer therapy, emphasizing the role of cell state
and cellular plasticity in driving resistance mechanisms. Dr. Tyner discusses the challenges of studying dynamic
resistance processes, the promise of targeting cell state plasticity to overcome therapeutic failure, and how
resistance trajectories evolve over time.
The discussion also highlights the importance of identifying the optimal window for intervention and the growing
role of collaborative science within the ARTNet Consortium in advancing cancer resistance research. Despite the
complexity of the problem, the episode reflects a strong sense of optimism about the future of precision oncology
and translational cancer research.
